Author:
Kafaja Suzanne,Furst Daniel E.,Pope Janet E.
Reference41 articles.
1. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2010;39(4):269–77.
2. Seibold JR, Tyndall A, Furst DE. Trial design: how must we move ahead? Rheumatology (Oxford). 2008;47(Suppl 5):v57–8.
3. Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol. 2002;29(9):1867–73.
4. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, Merkel P, Foeldvari I, Seibold J, Pittrow D, Polisson R, Strand V. Systemic sclerosis – continuing progress in developing clinical measures of response. J Rheumatol. 2007;34(5):1194–200, Review.
5. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE, EPOSS Group. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis. 2010;69(7):1360–3 [Epub 2010 May 14]. Review.